Optimization of a compound prescription for treating liver fibrosis.
- Author:
Liang HUANG
1
;
Linyan QI
;
Zhiliang CHEN
;
Yilei LI
;
Zhiyong WEN
Author Information
- Publication Type:Journal Article
- MeSH: Alkaloids; administration & dosage; Animals; Drug Therapy, Combination; Female; Glycyrrhizic Acid; administration & dosage; Liver Cirrhosis; chemically induced; drug therapy; Male; Phytotherapy; Quinolizines; administration & dosage; Rats; Rats, Sprague-Dawley; Thioacetamide
- From: Journal of Southern Medical University 2012;32(1):106-108
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo optimize a compound prescription for treatment of liver fibrosis with an improved therapeutic effect and low toxicity.
METHODSIn rat models of liver fibrosis induced by thioacetamide (TAA), the optimized prescription was screened based on a uniform design with 2-factor 5-level table using Uniform Design 3.0 software and tested using liver content of Hyp as the screening index. To verify the efficacy of the optimized prescription, the rat models of liver fibrosis were randomized into normal control group, model group, colchicine group and optimized prescription group, and the changes of hepatic Hyp content, serum HA, ALT, AST, and ALB levels, and the pathology liver fibrosis were observed after corresponding treatments.
RESULTSThe optimized prescription, which contained 70 mg/kg glycyrrhizin and 70 mg/kg matrine, showed a significant therapeutic effect against liver fibrosis in rats (Plt;0.05), and the effect was equivalent to that of colchicine (P>0.05).
CONCLUSIONUniform design is a valuable method in prescription optimization. The optimized compound prescription of matrine and glycyrrhizin has a significant effect in inhibiting liver fibrosis.
